Withdrawal Notice
This paper was originally published in Oncotarget Advance Online Publications on 01/02/2018.In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.
Clinical Research Papers:
A multicenter, randomized, controlled trial of rebamipide plus lansoprazole for the treatment of post-endoscopic submucosal dissection ulcers
Bin Yan1,*, Zhongsheng Lu1,*, Zhizheng Ge2, Side Liu3, Xuegang Guo4, Dean Tian5, Yuxiu Yang6, Xiaobo Li2, Wei Gong3, Zhiguo Liu4, Mei Liu5, Bingxi Zhou6, Kabing Zhao1, Jing Yang1 and Yunsheng Yang1
1Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing, China
2Department of Gastroenterology and Hepatology, Renji Hospital, Shanghai, China
3Department of Gastroenterology and Hepatology, Nanfang Hospital, Guangzhou, Guangdong Province, China
4Department of Gastroenterology and Hepatology, Xijing Hospital, Xian, Shanxi province, China
5Department of Gastroenterology and Hepatology, Tongji Hospital, Wuhan, Hubei province, China
6Department of Gastroenterology and Hepatology, Henan Provincial People’s Hospital, Zhengzhou, Henan Province, China
*These authors contributed equally to this work
Correspondence to:
Yunsheng Yang, email: [email protected]
Keywords: randomized clinical trial; endoscopic submucosal dissection; ulcer; lansoprazole; rebamipide
Received: September 29, 2017 Accepted: November 15, 2017 Published: January 02, 2018
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23127